Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

Vitality Awaiting CBD Drug Patents to Treat MS, Addiction, Stroke, Schizophrenia

Vitality Awaiting CBD Drug Patents to Treat MS, Addiction, Stroke, SchizophreniaLos Angeles-based cannabis biotech Vitality Biopharma, Inc. (OTCQB: VBIO) filed national patent applications in the US and Canada in October for cannabidiol (CBD) compounds effective in neural repair using remyelination, and is still waiting to hear results.

{{cta(’69f63bd3-e695-415f-8c83-b207c29317a6′)}}

Cannabidiol (CBD), a non-intoxicating cannabinoid the FDA already approved to treat epilepsy, is also known to relieve pain through modulation of the TRPV1 receptor. As a result, Vitality made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair.

The patent rights are based on work performed by the Myelin Repair Foundation (MRF), which assigned these rights to Vitality in 2016. The results were published in BMC Neuroscience. Researchers discovered several drugs useful in effecting remyelination, a form of nervous system regeneration critical to restoring lost function from multiple sclerosis. Emerging research also points to a role in addiction, stroke, and schizophrenia.

Vitality Biopharma is working with cannabinoids to discover treatments for neurological and inflammatory disorders. For more information, visit: www.vitality.bio or follow it on Facebook, Twitter and LinkedIn.

Want to learn more? Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.

Source Vitality press release

Vitality Awaiting CBD Drug Patents to Treat MS, Addiction, Stroke, Schizophrenia

About Cannin.com: Your Marijuana Stocks Resource

Cannin is your #1 resource for marijuana stocks. Our global team of experts evaluates all emerging marijuana stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best marijuana stock investments for 2020. 

Use Cannin as your resource for:

Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.

Many market analysts expect the legal marijuana industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in marijuana stocks is now. 

Are you interested in marijuana stocks like Curaleaf, Trulieve, Aurora Cannabis, or Charlotte’s Web,?

Are you looking to buy stock in marijuana companies for 2020? Interested in emerging penny marijuana stocks? Looking for the best Canadian marijuana stocks to invest in? We can help.

Predict price movements of marijuana stocks several hours in advance with our proprietary algorithmic stock trading software.

  • +25% Gains in 2020
  • +49.8% Gains in 2019
  • 108% Backtested since 2012

We’re so confident you’ll love our algotrading marijuana stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best marijuana stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Hemp Stocks to Buy